Skip to content

US · GRDN · MEDICAL - CARE FACILITIES

Guardian Pharmacy Services, Inc. (GRDN) intrinsic value and stock valuation

$46.94as of 2026-11-21 · Mkt cap 2.56B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Guardian Pharmacy Services, Inc. DCF and intrinsic value

InvestorsCraft values GRDN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from GRDN’s statements →

Guardian Pharmacy Services, Inc. Graham Number

Graham Number: $7.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Atlanta, GA 30339 guardianpharmacy.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$1.45B+14.5% 5y CAGRd
20182025
Net income
$49.2M+19.8% 5y CAGRd
20182025
Free cash flow
$80.7M+12.8% 5y CAGRd
20182025
Total equity
$217.9M+26.6% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$1.45B$1.23B$1.05B$908.9M$792.1M
Operating income$88.9M-$-62.92M$41M$52M$30.2M
Net income$49.2M-$-87.29M$23.9M$35.4M$16.3M
EPSd$777.6K-$-1.41M$392.8K$582.2K$268.1K
Operating cash flow$100.3M$58M$70.8M$48.5M$58.5M
Capital expenditure-$-19.58M-$-16.37M-$-14.56M-$-16.77M-$-9.28M
Free cash flow$80.7M$41.6M$56.3M$31.8M$49.2M
Total assets$412.7M$320.8M$271.2M$256.1M$235.9M
Total debt$37.1M$37.3M$69.2M$63M$55M
Net debt-$-28.48M$32.7M$68.4M$62.4M$40M
Total equity$217.9M$150M$59.9M$75.9M$53.3M
Cash and short-term investments$65.6M$4.66M$750K$610K$15M
Income statement
20252024202320222021
Revenue$1.45B$1.23B$1.05B$908.9M$792.1M
Cost of revenue$1.17B$984M$837.9M$723M$630.8M
Gross profit$282M$244.4M$208.3M$185.9M$161.3M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$193.1M$307.3M$167.4M$133.9M$131.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$193.1M$307.3M$167.4M$133.9M$131.1M
Cost and expenses$1.36B$1.29B$1.01B$856.9M$761.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$670K$3.28M$2.86M$1.93M$1.64M
Depreciation and amortization$22.3M$19.8M$18.2M$16.6M$16.5M
Ebitda$96.4M-$-43.43M$58.8M$68.2M$46.5M
Operating income$88.9M-$-62.92M$41M$52M$30.2M
Total other income/expenses, net-$-15.49M-$-3.56M-$-3.23M-$-2.33M-$-1.82M
Income before tax$73.4M-$-66.48M$37.7M$49.7M$28.3M
Income tax expense$24.5M$4.56M$0.00$0.00$0.00
Net income$49.2M-$-87.29M$23.9M$35.4M$16.3M
Weighted average shares outstanding$62.4M$62M$60.8M$60.8M$60.8M
Weighted average diluted shares outstanding$63.3M$62M$60.8M$60.8M$60.8M
Balance sheet
20252024202320222021
Cash and short-term investments$65.6M$4.66M$750K$610K$15M
Net receivables$101.6M$97.2M$77.3M$67.8M$55.3M
Inventory$43.4M$40.6M$36.7M$41.4M$33.1M
Total current assets$221.6M$152M$129.6M$120M$111.9M
Property, plant and equipment, net$90.2M$79M$73.2M$65.2M$51.7M
Goodwill and intangible assets$98.2M$84.2M$68M$70.5M$71.7M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$191M$168.8M$141.6M$136.1M$124M
Total assets$412.7M$320.8M$271.2M$256.1M$235.9M
Accounts payable$116.2M$102.4M$85.6M$78.1M$64.6M
Short-term debt$7.15M$10.6M$23.1M$16.3M$11.9M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$160.7M$144.1M$138M$112M$111.5M
Long-term debt$30M$26.7M$46M$46.6M$43.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$34M$26.7M$73.3M$68.2M$71M
Capital lease obligations$37.1M$37.3M$37.2M$32.1M$24.3M
Total liabilities$194.7M$170.8M$211.3M$180.2M$182.5M
Common stock$60K$60K$28.2M$42.7M$24.1M
Retained earnings$66.3M$17.1M$0.00$0.00$0.00
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$-180K
Total equity$217.9M$150M$59.9M$75.9M$53.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$37.1M$37.3M$69.2M$63M$55M
Net debt-$-28.48M$32.7M$68.4M$62.4M$40M
Cash flow statement
20252024202320222021
Net income$49.2M-$-71.03M$37.7M$49.7M$28.3M
Depreciation and amortization$22.3M$19.8M$18.2M$16.6M$16.5M
Stock-based compensation$13.9M$131.5M-$-6.09M-$-3.38M$13M
Change in working capital$6.38M-$-29.41M$15.6M-$-18.72M-$-1.47M
Accounts receivable-$-8.55M-$-25.48M-$-14.3M-$-16.79M-$-7.71M
Inventory-$-880K-$-1.15M$4.43M-$-8.12M-$-240K
Accounts payable$16.4M$13.2M$6.29M$13.4M$9.78M
Net cash provided by operating activities$100.3M$58M$70.8M$48.5M$58.5M
Investments in property, plant and equipment-$-19.58M-$-16.37M-$-14.56M-$-16.77M-$-9.28M
Acquisitions, net$0.00-$-14.71M-$-980K-$-2M-$-4.4M
Net cash used for investing activities-$-32.26M-$-30.41M-$-13.44M-$-17.9M-$-13.15M
Common stock issued$27.5M$119.8M$0.00$0.00$0.00
Common stock repurchased-$-29.04M-$-55.18M$0.00$0.00$0.00
Dividends paid$0.00-$-35.75M-$-38.42M-$-30.8M-$-17.36M
Net cash used for financing activities-$-7.07M-$-23.64M-$-57.23M-$-45.03M-$-36.79M
Net change in cash$61M$3.91M$140K-$-14.4M$8.56M
Cash at end of period$65.6M$4.66M$750K$610K$15M
Operating cash flow$100.3M$58M$70.8M$48.5M$58.5M
Capital expenditure-$-19.58M-$-16.37M-$-14.56M-$-16.77M-$-9.28M
Free cash flow$80.7M$41.6M$56.3M$31.8M$49.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Guardian Pharmacy Services, Inc.

        Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.

        CEO
        Fred Burke
        Employees
        3.6K
        Beta
        0.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Guardian Pharmacy Services, Inc. (GRDN)?

        Guardian Pharmacy Services, Inc. (GRDN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GRDN undervalued?

        GRDN trades at a price of $46.94 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.